UroGen Pharma Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| URGN | PMRA.F | CGON | QURE | OCUL | RARE | |
|---|---|---|---|---|---|---|
| Market cap | 1.41B | 1.17B | 6.00B | 1.62B | 1.57B | 1.75B |
| P/E (TTM) | — | 17.3 | — | — | — | — |
| Forward P/E | 10.4 | — | -22.4 | -7.8 | -4.8 | 76.1 |
| Price/book | -13.2 | 5.0 | 5.8 | 7.2 | 3.0 | -5.8 |
| Dividend yield | — | 1.54% | — | — | — | — |
| 1-year change | +22.09% | −9.28% | +70.60% | −16.28% | −32.83% | −44.56% |
| Today | −16.45% | +6.01% | +5.70% | −3.52% | +4.69% | +3.19% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All URGN news ›UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights
Nov 4, 2026 8:00am EST PRINCETON, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty…
UroGen Pharma GAAP EPS of -$0.03 misses by $0.13, revenue of $89M misses by $0.91M
UroGen Pharma Q3 results: EPS missed and revenue rose 223.9% year over year to $89M. - UroGen Pharma press release (URGN): Q3 GAAP EPS of -$0.03 misses by $0.13. - Revenue of $89M (+223.9% Y/Y) misses by $0.91M. - 1,538 activated sites of…
UroGen Pharma Ltd. (URGN) Q3 2026 Earnings Call Transcript
UroGen Pharma Ltd. (URGN) Q3 2026 Earnings Call November 4, 2026 10:00 AM EST Vincent Perrone - Senior Director of Investor RelationsElizabeth Barrett - President, CEO & DirectorMark Schoenberg - Chief Medical OfficerChristopher Degnan -…
More from 1 other outlet
UroGen Pharma Q3 revenue misses expectations on JELMYTO decline
TradingView UroGen Pharma Q3 revenue misses expectations on JELMYTO decline
UroGen Pharma management to meet with Oppenheimer
Meeting to be held in San Francisco on October 20, in Los Angeles on October 21-22 and Denver on October 23 hosted by Oppenheimer. Published fi... UroGen Pharma management to meet with Oppenheimer Meeting to be held in San Francisco on…
UroGen Pharma announces FDA acceptance of UGN-103 NDA
UroGen Pharma (URGN) announced FDA acceptance of the new drug application, or NDA, for investigational drug UGN-103 for intravesical solution fo... UroGen Pharma announces FDA acceptance of UGN-103 NDA UroGen Pharma (URGN) announced FDA…
AxoGen (NASDAQ:AXGN) Stock Price Target Raised at HC Wainwright
Posted by Defense World Staff on Oct 30th, 2026 AxoGen (NASDAQ:AXGN – Free Report) had its price objective lifted by HC Wainwright from $53.00 to $56.00 in a report issued on Thursday, Marketbeat reports. The firm currently has a buy…
INTRAGEL THERAPEUTICS LTD announced that it expects to receive $7 million in funding from UroGen Pharma Ltd.
INTRAGEL THERAPEUTICS LTD announced that it entered into an Investment Agreement for gross proceeds of $7,000,000 on August 20, 2026. The transaction included participation from new investor, UroGen... Published on 08/20/2026 at 10:05 am…
UroGen Pharma Ltd.: Relative Strength Chart - Stock Nasdaq
Compare UroGen Pharma Ltd. with the company of your choice via a Relative Strength chart. Real-time URGN price, Nasdaq stock exchange Relative Strength Chart UroGen Pharma Ltd. Biotechnology & Medical Research All financial news and data…
Oppenheimer Adjusts PT on UroGen Pharma to $60 From $50, Maintains Outperform Rating
UroGen Pharma has an average rating of buy and mean price target of $56.25, according to analysts polled by FactSet. Price: 46.43, Change: +6.51, Percent Change: +16.31 ... Biotechnology & Medical Research Oppenheimer Adjusts PT on UroGen…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com10
- marketscreener.com8
- seekingalpha.com3
- markets.businessinsider.com2
- defenseworld.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 27 articles, not a forecast.